Description
Using our intelligently designed and intuitive dataset, you can quickly understand how Sanofi, U.S. (SNY) is lobbying the U.S. government, how much they’re spending on it, and most importantly – the bills and specific issues on which they lobby.
Gain an informational edge with our Lobbying Data Intelligence. Perform analysis by company, lobbyist, lobbying firm, government agency, or issue.
For lobbying firms: understand your competitors. Understand who is registering with who. Gain insight on quarterly reports and specific issues other firms are lobbying on.
Our lobbying data is collected and aggregated from the U.S. Senate Office of Public Records from 1999-present and is updated on a regular basis. We utilize advanced data science techniques to ensure accurate data points are collected and ingested, match similar entities across time, and tickerize publicly traded companies that lobby.
Our comprehensive and advanced lobbying database is completed with all the information you need, with more than 1.6 million lobbying contracts ready-for-analysis. We include detailed information on all aspects of federal lobbying, including the following fascinating attributes, among much more:
1. Clients: The publicly traded company, privately owned company, interest group, NGO, or state or local government that employs or retains a lobbyist or lobbying firm.
2. Registrants (Lobbying Firms): Either the name of the lobbying firm hired by the client, or the name of the client if the client employs in-house lobbyists.
3. Lobbyists: The names and past government work experience of the individual lobbyists working on a lobbying contract. 3. General Issues: The general issues for which clients lobby on (ex: ENV – Environment, TOB – Tobacco, FAM – Family Issues/Abortion).
4. Specific Issues: A long text description of the exact bills and specific issues for which clients lobby on.
5. Bills Lobbied On: The exact congressional bills and public/private laws lobbied on, parsed from lobbying report specific issues (ex: H.R. 2347, S. 1117, Tax Cuts and Jobs Act).
6. Agencies Lobbied: The names of one or more of 250+ government agencies lobbied on in the contract (ex: White House, FDA, DOD).
7. Foreign Entities: The names and origin countries of entities affiliated with the client (ex: BNP Paribas: France).
Gain access to our highly unique and actionable U.S. lobbying database. Further information on LobbyingData.com and our alternative datasets and database can be found on our website, or by contacting [email protected].
Frequently Asked Questions
What is Sanofi, U.S. (SNY) lobbying for?
Summary of Lobbying Data:
– Lobbying Firms: Forbes-Tate, Pllc, Williams And Jensen
– General Issues: Taxation/Internal Revenue Code, Medical/Disease Research/Clinical Labs, Health Issues, Medicare/Medicaid, Budget/Appropriations
– Specific Issues: Affordable Insulin Now Act., General education about FDA approval policies and NIH research activities. Reauthorization of the Prescription Drug User Fee Act. H.R. 7667, Build Back Better Act. H.R. 6833, More Cures Act of 2021. Policies impacting U.S. address to the Covid-19 pandemic. H.R. 5376, Affordable Insulin Now Act. Improving Needed Safeguards for Users of Lifesaving Insulin Now (INSULIN) Act, Issues related to prescription drug pricing., General education about federal policies impacting pharmaceutical development, and for other purposes (P.L.117-180), P.L. 117-2, and reimbursement, H.R. 1319. Policies impacting vaccine access and disease prevention., Build Back Better Act., 2022., including FDA User Fee Reauthorization Act of 2022., Issues related to prescription drug pricing, the Food and Drug Amendments of 2022 and S.4348, and the Orphan Drug Tax Credit and interaction with other tax provisions; proposed changes to corporate and international taxation; H.R. 5376., Elijah E. Cummings Lower Drug Costs Now Act and H.R. 19, H.R. 1319. Policies impacting vaccine access and disease prevention., H.R. 1319. Policies impacting vaccine access and disease prevention. Prevention including provisions included in the Consolidated Appropriations Act, Lower Costs, including vaccine development and vaccine administration. Provisions included in the Consolidated Appropriations Act, and reimbursement. Policies impacting public health preparedness and prevention. H.R. 3, Issues related to prescription drug pricing; Issues related to Section 340B of the Public Health Service Act; Issues related to H.R.5376 – Build Back Better Act; Issues related to H.R.2471 – Consolidated Appropriations Act, 2022; Issues related to the prescription drug user fee acts., the FDA Safety and Landmark Act. H.R.6833 Making continuing appropriations for fiscal year 2023, and reimbursement. Policies impacting public health preparedness and prevention. H.R. 3, including the American Rescue Plan Act
– Government Agencies: Senate, House of Representatives
One could infer that Sanofi, U.S. is lobbying on these issues in order to influence legislation and regulations that may impact their operations and profitability, particularly in the pharmaceutical industry. The specific issues they lobbied on suggest they are concerned with issues such as prescription drug pricing, access to medicines, research and development funding, and vaccine access and prevention policies. The fact that they hired multiple lobbying firms and lobbied both the Senate and House of Representatives suggests a concerted effort to influence policymaking at the federal level.
